284 related articles for article (PubMed ID: 34689339)
21. Real-world Data and Evidence to support a switch in status from Prescription drug to Over the Counter drug as applied by the EMA, the US FDA, the MHRA, and the BfArM.
Kühler TC; Ateka A; Lassoued Z; Routhier FX; Mékary-Sawaya S
Clin Ther; 2024 Mar; 46(3):208-216. PubMed ID: 38278703
[TBL] [Abstract][Full Text] [Related]
22. Use of the conditional marketing authorization pathway for oncology medicines in Europe.
Hoekman J; Boon WP; Bouvy JC; Ebbers HC; de Jong JP; De Bruin ML
Clin Pharmacol Ther; 2015 Nov; 98(5):534-41. PubMed ID: 26080745
[TBL] [Abstract][Full Text] [Related]
23. How can real-world evidence aid decision making during the life cycle of nonprescription medicines?
Csoke E; Landes S; Francis MJ; Ma L; Teotico Pohlhaus D; Anquez-Traxler C
Clin Transl Sci; 2022 Jan; 15(1):43-54. PubMed ID: 34405554
[TBL] [Abstract][Full Text] [Related]
24. A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why.
Kashoki M; Hanaizi Z; Yordanova S; Veselý R; Bouygues C; Llinares J; Kweder SL
Clin Pharmacol Ther; 2020 Jan; 107(1):195-202. PubMed ID: 31306483
[TBL] [Abstract][Full Text] [Related]
25. The use of real-world evidence to support FDA post-approval study requirements for oncology drugs.
Zettler ME
Expert Rev Anticancer Ther; 2022 Jun; 22(6):657-666. PubMed ID: 35512688
[TBL] [Abstract][Full Text] [Related]
26. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review.
Goring S; Taylor A; Müller K; Li TJJ; Korol EE; Levy AR; Freemantle N
BMJ Open; 2019 Feb; 9(2):e024895. PubMed ID: 30819708
[TBL] [Abstract][Full Text] [Related]
27. [The application of real-world evidence in drug regulatory decision-making].
Wicherski J; Haenisch B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2024 Feb; 67(2):149-154. PubMed ID: 38214723
[TBL] [Abstract][Full Text] [Related]
28. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?
Khosla S; White R; Medina J; Ouwens M; Emmas C; Koder T; Male G; Leonard S
F1000Res; 2018; 7():111. PubMed ID: 30026923
[TBL] [Abstract][Full Text] [Related]
29. Use of real-world evidence for oncology clinical decision making in emerging economies.
Petracci F; Ghai C; Pangilinan A; Suarez LA; Uehara R; Ghosn M
Future Oncol; 2021 Aug; 17(22):2951-2960. PubMed ID: 34044583
[TBL] [Abstract][Full Text] [Related]
30. The Use of Real-World Evidence for Regulatory Decisions in China.
Xu J; Wu W; Zhang X; Ren Y; Yao M; Liu M; Zou K; Wang W; Sun X
Clin Pharmacol Ther; 2024 Jul; 116(1):82-95. PubMed ID: 38566457
[TBL] [Abstract][Full Text] [Related]
31. Use of Real-World Evidence in Neuroscience-Related New Drug and Biologics License Applications for Novel Therapeutics.
Bloomfield-Clagett B; Rahman M; Smith K; Concato J
Clin Pharmacol Ther; 2023 Nov; 114(5):1002-1005. PubMed ID: 37548904
[TBL] [Abstract][Full Text] [Related]
32. The effect of adding real-world evidence to regulatory submissions on the breadth of population indicated for rare disease medicine treatment by the European Medicines Agency.
Jandhyala R
J Pharm Policy Pract; 2022 May; 15(1):36. PubMed ID: 35509059
[TBL] [Abstract][Full Text] [Related]
33. Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe.
Jonker CJ; Bakker E; Kurz X; Plueschke K
Front Pharmacol; 2022; 13():924648. PubMed ID: 35991868
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency.
Regnstrom J; Koenig F; Aronsson B; Reimer T; Svendsen K; Tsigkos S; Flamion B; Eichler HG; Vamvakas S
Eur J Clin Pharmacol; 2010 Jan; 66(1):39-48. PubMed ID: 19936724
[TBL] [Abstract][Full Text] [Related]
35. Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned.
Ro SK; Zhang W; Jiang Q; Li XN; Liu R; Lu CC; Marchenko O; Sun L; Zhao J
Ther Innov Regul Sci; 2023 Jul; 57(4):899-910. PubMed ID: 37179264
[TBL] [Abstract][Full Text] [Related]
36. Real-World Evidence: A Primer.
Dang A
Pharmaceut Med; 2023 Jan; 37(1):25-36. PubMed ID: 36604368
[TBL] [Abstract][Full Text] [Related]
37. Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies.
Harricharan S; Curran E; Lin HM; Walton L; Gurjar K; Nguyen K; Forsythe A
Future Oncol; 2023 Mar; 19(8):603-616. PubMed ID: 37083358
[TBL] [Abstract][Full Text] [Related]
38. EU-funded initiatives for real world evidence: descriptive analysis of their characteristics and relevance for regulatory decision-making.
Plueschke K; McGettigan P; Pacurariu A; Kurz X; Cave A
BMJ Open; 2018 Jun; 8(6):e021864. PubMed ID: 29903798
[TBL] [Abstract][Full Text] [Related]
39. Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trials.
Lasala R; Logreco A; Romagnoli A; Santoleri F; Musicco F; Costantini A
Eur J Clin Pharmacol; 2020 Jun; 76(6):843-850. PubMed ID: 32125472
[TBL] [Abstract][Full Text] [Related]
40. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
